All In Biotech

Investigational drug · Phase 3

ZG006

Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

8

8 still active

All registered trials

11

Any phase or sponsor naming "ZG006"

First trial start

2023

Oct 27, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ZG006", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neuroendocrine Carcinoma
  • Small Cell Lung Cancer
  • Solid Tumor
  • Small-cell Lung Cancer
  • Neuroendocrine Prostate Cancer
  • Neuroendocrine Cancer

Approved drugs for the same conditions: Small cell lung cancer · Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "ZG006" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Neuroendocrine Carcinoma

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • GocatamigHPN328, MK-6070Phase 34 trials

    Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer

  • CVM-1118TRX-818Phase 22 trials

    TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.